LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, ...
Needham Remains a Buy on Phathom Pharmaceuticals (PHAT)
Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: HilleVax, Inc (HLVX), Lexicon Pharmaceuticals (LXRX) and Arvinas Holding Company (ARVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on HilleVax, Inc (HLVX – Research Report), Lexicon ...
Houston-area company may be developing next hot weight-loss drug
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
Swiss National Bank Grows Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
Swiss National Bank increased its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 34.4% during the 4th ...
American Association of Individual Investors2d
Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 25.32%
Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 25.32%, which has investors questioning if this is right time to buy.
MedPage Today3d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery Disease
CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
The Woodlands-based company strikes obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...
Lexicon Pharmaceuticals’ (LXRX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...
BioWorld4d
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal
As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, ...
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.